Veraxa Biotech is a clinical-stage biotechnology company that develops antibody-based cancer therapies. The company specializes in two therapeutic areas: Antibody-Drug Conjugates (ADCs) and T Cell Engagers (TCEs). Its ADC platform utilizes click chemistry to attach toxic payloads to antibodies, while its BiTAC-TCE platform uses bispecific constructs that activate only when they encounter two specific antigens on a tumor cell surface. Veraxa's lead candidate is VX-A901, an anti-FLT3 antibody that has completed Phase I trials for acute myeloid leukemia. Other pipeline programs are in preclinical stages and target various solid tumors. Beyond drug development, Veraxa maintains a microfluidic antibody screening business called Hitmaster, which it licenses to other biotechnology companies. Veraxa is currently pre-revenue and follows a business model centered on advancing clinical programs to reach licensing deals, pharma partnerships, or commercialization. The company funds its research and development through capital markets and partnership milestones. Based in Switzerland with operations in Germany, Veraxa was formed through the merger of several specialized biotech firms to combine antibody modulation and screening technologies. The company's strategy relies on using its precision conjugation and conditional activation platforms to create therapies with better safety profiles than standard treatments.